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Abstract
Background: Perioperative anaemia leads to impaired oxygen supply with a risk of vital organ ischaemia. In healthy
and fit individuals, anaemia can be compensated by several mechanisms. Elderly patients, however, have less
compensatory mechanisms because of multiple co-morbidities and age-related decline of functional reserves. The
purpose of the study is to evaluate whether elderly surgical patients may benefit from a liberal red blood cell (RBC)
transfusion strategy compared to a restrictive transfusion strategy.
Methods: The LIBERAL Trial is a prospective, randomized, multicentre, controlled clinical phase IV trial randomising
2470 elderly (≥ 70 years) patients undergoing intermediate- or high-risk non-cardiac surgery. Registered patients will
be randomised only if Haemoglobin (Hb) reaches ≤9 g/dl during surgery or within 3 days after surgery either to the
LIBERAL group (transfusion of a single RBC unit when Hb ≤ 9 g/dl with a target range for the post-transfusion Hb
level of 9–10.5 g/dl) or the RESTRICTIVE group (transfusion of a single RBC unit when Hb ≤ 7.5 g/dl with a target
range for the post-transfusion Hb level of 7.5–9 g/dl). The intervention per patient will be followed until hospital
discharge or up to 30 days after surgery, whichever occurs first. The primary efficacy outcome is defined as a
composite of all-cause mortality, acute myocardial infarction, acute ischaemic stroke, acute kidney injury (stage III),
acute mesenteric ischaemia and acute peripheral vascular ischaemia within 90 days after surgery. Infections
requiring iv antibiotics with re-hospitalisation are assessed as important secondary endpoint. The primary endpoint
will be analysed by logistic regression adjusting for age, cancer surgery (y/n), type of surgery (intermediate- or high-
risk), and incorporating centres as random effect.
(Continued on next page)
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Discussion: The LIBERAL-Trial will evaluate whether a liberal transfusion strategy reduces the occurrence of major
adverse events after non-cardiac surgery in the geriatric population compared to a restrictive strategy within 90
days after surgery.
Trial registration: ClinicalTrials.gov (identifier: NCT03369210).
Keywords: Red blood cell transfusion, anaemia, surgery, elderly patients
Background
Perioperative anaemia leads to impaired oxygen supply
with a risk of vital organ ischaemia resulting in major
events such as myocardial infarction, ischaemic stroke,
acute kidney injury, or acute mesenteric ischaemia. In
healthy and fit individuals, perioperative anaemia can be
compensated by several mechanisms that preserve oxy-
gen transport and oxygen delivery. Therefore, current
guidelines recommend a restrictive red blood cell (RBC)
transfusion strategy in non-bleeding asymptomatic stable
patients [1, 2].
Several trials revealed that restrictive transfusion is as
safe as compared to a liberal strategy. It is noteworthy that
the majority of trials only included a limited proportion of
elderly patients [3–7]. The compensatory mechanisms,
however, are impaired in old and frail patients. Elderly
patients have an increased prevalence of cardiovascular co-
morbidities and decline of functional reserves. In 70 year
old patients, e.g. arterial hypertension is present in
75% [8], diabetes mellitus in 25% [9], and atrial fibril-
lation in 10% [10]. Therefore, normal anaemia-related
compensatory mechanisms are severely impaired in
elderly patients, which may result in greater vulner-
ability to anaemia-related ischaemic events and peri-
operative complications [11, 12].
Carson et al. studied 110 patients with acute coronary
syndrome with a mean age of 71 years and found fewer
major cardiac events and deaths if red blood cell (RBC)
transfusion increased Hb > 10 g/dl compared to a restrictive
strategy (10.9% vs. 25.5%) [13]. One small trial including 40
patients with hip fracture compared a liberal (RBC transfu-
sion if Hb < 10 g/dl) and a restrictive group (if Hb < 8 g/dl),
and demonstrated a 2.5-times higher 30-day mortality in
the restrictive group [14]. The same group performed a
subsequent trial enrolling 2016 patients older than 50 years
of age, who had either a history of or risk factors for cardio-
vascular disease, and whose Hb level were < 10 g/dl after
hip-fracture surgery. A restrictive strategy (Hb < 8 g/dl) was
not superior to a liberal transfusion strategy (Hb < 10 g/dl)
regarding mortality rate or inability to walk on 60-days
follow-up [15].
Until now, the available evidence for transfusion criteria
is not sufficient for elderly patients. Thus, it is unclear
whether current practice and guidelines apply in a geriat-
ric population [16]. Accordingly, major uncertainties exist
among clinicians, and current clinical practice is vari-
able [17, 18]. As a result of demographic changes
clinicians have to handle a large number of elderly
surgical patients with perioperative anaemia and rele-
vant need for RBC transfusion. More than 50% of all
RBC transfusions are used in elderly patients in daily
practice, and current population dynamics will lead to
an increasing demand for RBC transfusions in the
old-age patient group [19].
We hypothesise that a liberal transfusion strategy re-
duces the occurrence of major adverse events defined
as the composite of all-cause mortality and severe ischae-
mic events within 90 days in elderly patients undergoing
non-cardiac surgery compared to a restrictive transfusion
strategy.
Methods
The LIBERAL-Trial is a prospective, randomized, open,
multicentre, controlled clinical phase IV trial targeting a
sample size of 2470 elderly surgical patients in 15–20
German sites.
Study population
A two-step approach will be used (Figs. 1 and 2): In step I,
elderly patients (age ≥ 70 years) will be registered if sched-
uled for elective, non-cardiac surgery of intermediate or
high risk. Written informed consent is obtained from the
patients themselves or from their legally authorised repre-
sentative/legal guardian.
Risk assessment follows ESC/ESA guidelines: surgery-
related risk of cardiovascular death and myocardial
infarction [20]. Intermediate risk surgery (30-day risk 1–
5%) includes e.g. intraperitoneal surgery (splenectomy,
hiatal hernia), peripheral arterial angioplasty, endovascular
aneurysm repair, as well as head and neck, major
neurological/orthopaedic (hip and spine), major uro-
logical, major gynaecological, intra-thoracic surgery.
High risk surgery (30-day risk > 5%) includes e.g. aortic
and major vascular, open limb revascularisation, duodeno-
pancreatic, liver resection, oesophagectomy, adrenal resec-
tion, total cystectomy.
Registered patients will be randomised later only if
and as soon as Hb reaches ≤9 g/dl during surgery
(=day 0) or day 1, 2, or 3 after surgery (step II). If
Hb remains > 9 g/dl patients do not enter the main
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Fig. 1 (See legend on next page.)
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study but vital status (all-cause mortality) will be deter-
mined 90 days after surgery. Mild drop of haemoglobin <
9 g/dl due to induction of anaesthesia before skin incision
is permitted and not an exclusion criteria.
Exclusion criteria at registration comprise preoperative
severe anaemia with Hb level < 9 g/dl, chronic kidney in-
jury requiring dialysis, suspected lack of compliance with
follow-up procedures, expected death within 3months,
participation in other interventional trials or previous
participation in our trial, temporary inability to provide
informed consent with absence of a legally authorised
representative/legal guardian, and preoperative autologous
blood donation. Additional exclusion criteria at random-
isation exclude patients who experienced any component
of the composite endpoint or received any allogeneic
blood transfusion since registration.
(See figure on previous page.)
Fig. 1 Schedule of Assessments and Procedures. X: assessments for all registered patients / •: additional assessments for randomised patients. 1
Randomisation: as soon as haemoglobin ≤9 g/dl during surgery (=day 0) or day 1, 2, or 3 after surgery, registered consenting patients will be
randomised. Re-evaluation of inclusion−/exclusion criteria before randomisation only refers to obvious occurrence of any component of the
composite endpoint and any allogeneic blood transfusion after registration (chapter 4.2.2.). No specified diagnostics are scheduled. 2a
Haemoglobin levels will be determined from blood samples (primarily BGA measurement mainly as part of the patient’s usual care) at least daily
before randomisation. 2b Mild drop of haemoglobin < 9 g/dl due to induction of anaesthesia before skin incision is permitted and not an
exclusion criteria. 2c Haemoglobin levels will be determined from blood samples (primarily BGA measurement mainly as part of the patient’s usual
care) at any time during or after randomisation until hospital discharge (up to 30 days after surgery; at least every 3 days), and after each
transfused unit. Creatinine levels will be determined as part of the patient’s usual care at any time during or after randomisation until hospital
discharge (or up to 30 days after surgery; at least every 7 days). 3 Intra-/Postoperative Intervention: Duration of intervention per patient: from intra
−/postoperative randomisation until hospital discharge or 30 days after surgery, whichever occurs first. Physicians will be instructed to transfuse
RBC units each time haemoglobin is lower than the randomised threshold and as soon as possible. The randomised target post-transfusion Hb
level needs to be reached each time within 24 h upon receipt of lab result at the latest
Fig. 2 Study intervention. Hb levels will be determined from blood samples (*) mainly as part of the patient’s usual care at any time during or after
surgery (up to 30 days after surgery; at least every 3 days), and after each transfused unit. Consenting patients will be registered (Step I) and will be
randomised as soon as Hb falls ≤9 g/dl during surgery (=day 0) or day 1, 2, or 3 after surgery. Physicians will be instructed to transfuse RBC units each
time Hb is lower the defined threshold and as soon as possible. The target post-transfusion Hb level needs to be reached within 24 h upon receipt of
lab result at latest. The intervention per patient will be followed until hospital discharge or up to 30 days, whichever occurred first, comparable to
recent large trials [5–7, 15]. In case of any massive or life-threatening bleeding, the single-unit policy should be paused
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Randomisation and Intervention
If Hb intra- or postoperatively reaches ≤9 g/dl (despite
possible autologous transfusion) determined from blood
samples mainly as part of the patient’s standard care
at any time during surgery (=day 0) or day 1, 2, or 3
after surgery, registered patients will be randomised
either to
 LIBERAL group: patients receive a single RBC
unit each time Hb reaches ≤9 g/dl (≤ 5.6 mmol/l)
with a target range for the post-transfusion Hb level
of 9–10.5 g/dl (5.6–6.5 mmol/l), or
 RESTRICTIVE group: patients receive a single
RBC unit each time Hb reaches ≤7.5 g/dl (≤ 4.7
mmol/l) with a target range for the post-transfusion
Hb level of 7.5–9 g/dl (4.7–5.6 mmol/l).
The target post-transfusion Hb level needs to be
reached within 24 h upon receipt of triggering lab re-
sult. The intervention per patient will be followed
until hospital discharge or up to 30 days after surgery,
whichever occurred first. Physicians will be allowed to
refuse to transfuse, or transfuse patients irrespective
of the group assignment in exceptional cases, e.g. hyper-
volaemia, symptomatic anaemia with physiological trig-
gers of anaemic hypoxia, or massive/life-threatening
bleeding, but must document the reason(s) in the
study eCRF.
Central internet randomisation at the Clinical Trial
Centre Leipzig uses block randomisation with vari-
able block length stratified by centre. For urgent
randomisation or in case of internet unavailability
randomisation can be performed using sealed enve-
lopes. Envelope randomisations will be checked dur-
ing on-site monitoring.
All trial patients will receive standard perioperative
care. The patients in both groups will not be exposed
to additional risk since transfusion-strategy studies al-
most showed the same results. Hb transfusion thresh-
olds used in previous studies varied from 7 to 10 g/dl
for the restrictive and from 9 to 13 g/dl for the liberal
group, respectively [5, 6, 15]. In addition RBC trans-
fusion is the main treatment option for anaemia due to
surgical blood loss. All patients benefit from intensive
monitoring and consequently early detection of any de-
crease of Hb-level.
Trial Drug
The strategies under evaluation use different Hb levels as
trigger for RBC transfusions and aim at different target
ranges of Hb levels to be maintained. The trial drug
will be manufactured and used as in standard care.
Only commercially available approved RBC units will
be used within this clinical trial and a list of these
approved RBCs is online available (http://www.pei.de/
DE/arzneimittel/blutprodukte/blutkomponenten-zur--
transfusion/erythrozytenkonzentrate/erythrozytenkon-
zentrate-node.html). RBCs are provided by the local
blood bank according to clinical routine considering
the requirements of § 63i AMG. This will assure the
participants’ safety, the traceability and identification
of the RBCs given. Therefore, a special labelling of the
RBCs for the trial according to § 42 AMG and § 5
GCP-V is not necessary.
Endpoints
The primary efficacy outcome is a binary composite of
death from any cause and anaemia-associated, ischaemic
events (defined as acute myocardial infarction, acute
stroke, acute kidney injury stage III, acute mesenteric is-
chaemia, acute peripheral vascular ischaemia) within 90
days after surgery. With the proposed composite, we as-
sess relevant anaemia-associated ischaemic events encom-
passing five different organs (brain, heart, kidney, gut,
limbs) where the assigned Hb level/transfusion strategy
will likely have an effect.
The primary efficacy outcome is defined as a compos-
ite of (within 90 days after surgery):
I. All-cause mortality is defined as death from any
cause.
II. Acute myocardial infarction confirmed by a
cardiologist.
III. Acute ischaemic stroke confirmed by a
neurologist.
IV. Acute kidney injury (stage III) is defined
according to the Kidney Disease Improving Global
Outcomes criteria: Increase of plasma creatinine
level ≥ 3 times within a time window of 7 days or
initiation of renal replacement therapy [21].
(Serum creatinine concentration will be measured at
least every 7 days until hospital discharge. Urine out-
put criteria will not be used to define acute kidney
injury because most of hospital do not mandate hourly
urine output measurements on all patients, and be-
cause of the likelihood of inaccurate measurement in
the substantial number of patients without urinary
catheters.)
V. Acute mesenteric ischaemia is defined as
ischaemia confirmed by intervention (abdominal
surgery or mesenteric angiography).
VI. Acute peripheral vascular ischaemia is defined as
a new non-thrombotic compromised circulation in
a limb confirmed by angiography and/or leading to
surgery.
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After hospital discharge, events will only be considered
as present if they lead to hospital re-admission or death.
Direct transfer to another hospital will not be defined as
re-admission.
Infection was not included into the composite end-
point since more transfusions may reduce ischaemic
events, but might show a counter effect increasing the
infection risk.
Secondary endpoints
Secondary outcome measures are the following:
 The occurrence of any individual component of the
composite at hospital discharge, at 90 days, and 1
year after surgery.
 Proportion of patients receiving RBC transfusion
and the number of units transfused.
 Total length of stay in the intensive care unit and in
hospital from randomisation to discharge (for
strategy comparison); in addition, total length of stay
in the intensive care unit and in hospital from
admission to discharge will be used for descriptive
purposes.
 The occurrence of acute kidney injury (stage I or II)
defined according to the Kidney Disease Improving
Global Outcomes criteria [21] (stage I: increase of
plasma creatinine level ≥ 1.5–1.9 times baseline
or ≥ 0.3 mg/dl within 48 h; stage II: increase of
plasma creatinine level ≥ 2–2.9 times baseline
within a time window of 7 days) during the initial
hospital stay.
 Time to (first) infection (infection requiring
therapeutic intravenous antibiotic treatment
(pneumonia, wound infection, sepsis, central line
associated blood stream infection [21–23])) during
the initial hospital stay or leading to hospital re-
admission within 90 days after surgery.
 Time to (first) re-hospitalisation within 90 days.
 Functional status (assessed by Barthel Index [24, 25]
by telephone questionnaire).
 Health-related quality of life (assessed by EuroQoL EQ-
5D [26, 27] and 12-itemWorld Health Organisation
Disability Assessment ScheduleWHODAS 2.0 [28] by
telephone questionnaire).
Sample size considerations
For the primary endpoint, we expect an overall compos-
ite complication rate (OCCR) of about 25% at 90 days
after surgery. This guestimate is based on a subgroup of
elderly patients included in a large observational study
in the field of Patient Blood Management [29], which
reported most of the endpoint components, and is also
based on the assumption that about 25–40% of regis-
tered patients will be randomised.
The effect size to be detected is set to an odds ra-
tio of OR = 0.765. The available evidence on treat-
ment differences from randomised trials concerning
the old age group is sparse and inconsistent. There-
fore, we choose an effect size, which is relevant from
a clinical perspective. Assuming an OCCR of 25%,
an odds ratio of OR = 0.765, corresponding to a 5%
reduction in OCCR from 27.5% to 22.5% or risk re-
duction of 18%, would justify switching to the liberal
transfusion strategy.
The target sample size is N = 2470 randomised patients.
Randomisation of 2 × 1176 = 2352 patients is required
using a two-sided significance level of 5% and requiring
power of 80% for a test of the null-hypothesis OR = 1 ver-
sus OR = 0.765 based on the normal approximation to log
(OR). We allow for a dropout rate of up to 5%.
Statistical analysis
The full analysis set for the primary efficacy analysis will be
as close as possible to the ideal implied by the intention-
to-treat principle and includes all randomised subjects. A
secondary per-protocol analysis of the primary outcome
will be performed in all patients without major protocol
violations.
Most endpoints will be analysed with scale-appropriate
generalised linear mixed models adjusting for age, can-
cer surgery (y/n), type of surgery (intermediate- or
high-risk), and incorporating centres as random effect.
Further baseline clinical variables may be entered in
secondary analyses.
For the primary endpoint, logistic regression will be
used to estimate the treatment effect on the odds ratio
scale with two-sided 95% confidence intervals pro-
vided. Secondarily, also point estimates and confi-
dence intervals for the rate difference and the relative
risk will be provided. The test of the null hypothesis
that the odds ratio concerning the composite endpoint
is equal to one will be tested using the Wald statistic
for the coefficient of the treatment effect in the logistic
regression.
Interim analyses
One formal unblinded interim analysis is scheduled after
about 1450 patients with 90-day endpoint information in
order to detect early superiority. This interim analysis
will use a significance level of alpha = 0.001 such that
the final analysis does not require adjusting for multiple
testing. With this interim analysis, we will have 80%
power to detect an odds ratio of 0.6, which corresponds
to an OCCR difference in the order of 10%.
If the interim analysis turns out significant, the trial
will be stopped, unless the Data Monitoring Safety Board
(DMSB) recommends otherwise. The responsible study
Meybohm et al. Trials          (2019) 20:101 Page 6 of 10
biometrician will perform the formal interim analysis,
write a strictly confidential report and discuss the results
exclusively with the Data Monitoring Safety Board. If the
DSMC recommends continuing with the trial, the Spon-
sor, the steering committee, the investigators, and the
study team will only receive the information that the in-
terim analysis for early superiority was performed and
discussed with the DSMC and that the trial continues.
All respective documents and analysis scripts are kept on
a dedicated file system to which only the biometrician and
his assistant have access rights.
Planned exploratory sub-group analyses
We hypothesise that the benefit from a liberal transfu-
sion strategy increases with declining anaemia compen-
satory capacity.
We will therefore perform exploratory subgroup ana-
lyses by
 Age (< 80 versus ≥80 years),
 Gender (male/female),
 American Society of Anaesthesiology Physical Status
classification [30],
 presence of cancer (y/n),
 ischaemic heart disease (y/n),
 heart failure (y/n),
 peripheral vascular disease (y/n),
 previous stroke (y/n),
Any resulting hypothesis requires confirmation in in-
dependent data.
Analysis in the larger set of all registered patients
We collect course of Hb levels during surgery (= day 0)
or day 1, 2, 3 after surgery and the vital status at day 90
(all-cause mortality) for all registered patients.
The prognostic value of delta Hb (difference pre-op
Hb and Hb on day three) and Barthel index on short
term mortality will be analysed adding these factors to
the generalised linear mixed model specified above.
Clinical study monitoring
On-site monitoring follows a risk-adapted approach
[31, 32]. Pre-study, initiation, regular, and closeout
visits will be performed in all centres. The first regular
visit takes place after discharge or day 30 after surgery
of the first 3 randomized patients, the following visits
will be performed after the discharge of additionally 15
more patients, but at least once a year. The intention of
the visits will be to achieve high protocol compliance
and data quality, as well as to ensure patients’ safety
and rights.
Central monitoring will include a timely query man-
agement process based on consistency and plausibility
checks combined with a dunning process for missing
documentation. In addition, the trial biometrician per-
forms statistical monitoring regularly in order to detect
general and centre-specific problems in key study pro-
cesses. Quality endpoints include accrual rate, rate of
dropouts and protocol violations, promptness of ran-
domisation when anaemia emerges, adherence to the
assigned transfusion strategies, as well as timeliness of
documentation.
Discussion
The transfusion of allogenic RBC units is the standard
procedure to treat peri- and postoperative severe an-
aemia. More than 50% of all RBC transfusions are used
in old and frail patients, and current population dynam-
ics in most developed countries will lead to an increas-
ing demand for RBC transfusions [19]. Elderly patients
have an increased prevalence of cardiovascular comor-
bidities and decline of functional reserves. Therefore,
anaemia-related compensatory mechanisms are severely
impaired in elderly patients, which may result in greater
vulnerability to anaemia-related ischaemic events and
perioperative complications [11, 12].
Here, the LIBERAL-Trial will provide a definite answer
for this patient group whether a liberal transfusion strat-
egy reduces the occurrence of major adverse events de-
fined as the composite of all-cause mortality and severe
ischaemic events within 90 days after non-cardiac sur-
gery compared to a restrictive strategy.
Potential limitations might refer to cross-over between
groups, needing to ‘register’ a large number of patients,
lack of recruiting, and drop-out due to various protocol
violations.
Trial Status
Study protocol (V3.0) was finalised at 17th of October
2017. This trial was registered at https://clinicaltrials.-
gov/ct2/show/NCT03369210 (identifier: NCT03369210)
at 12th of November 2017. Recruitment and enrolment
of the patients started in January 2018, more than 200
patients have been registered and more than 100 rando-
mised so far. The planned recruitment lasts 36 months.
Additional file
Additional file 1: SPIRIT 2013 Checklist. Recommended items to address
in a clinical trial protocol and related documents*. (DOCX 52 kb)
Abbreviations
AMG: Arzneimittelgesetz; BGA: blood gas analysis; eCRF: electronic case
report form; GCP: Good clinical practice; Hb: haemoglobin; OCCR: overall
composite complication rate; RBC: red blood cell
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